for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Apollo Endosurgery Inc

APEN.OQ

Latest Trade

2.81USD

Change

-0.04(-1.40%)

Volume

2,100

Today's Range

2.81

 - 

2.99

52 Week Range

2.52

 - 

4.21

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.85
Open
2.99
Volume
2,100
3M AVG Volume
0.29
Today's High
2.99
Today's Low
2.81
52 Week High
4.21
52 Week Low
2.52
Shares Out (MIL)
20.94
Market Cap (MIL)
60.32
Forward P/E
-2.20
Dividend (Yield %)
--

Latest Developments

More

Apollo Endosurgery, Inc. Reports Third Quarter 2019 Results

Apollo Endosurgery Files Prospectus Relates To Proposed Resale From Time To Time Of Up To 8 Mln Shares Of Common Stock By Selling Stockholders

Apollo Endosurgery, Inc. Reports Second Quarter 2019 Results

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Apollo Endosurgery Inc

Apollo Endosurgery, Inc., formerly Lpath, Inc., is a medical device company. The Company is focused on less invasive therapies for the treatment of obesity, as well as other gastrointestinal disorders. The Company's device-based therapies are an alternative to invasive surgical procedures. The Company offers products in over 80 countries. The Company's products include ORBERA, LAP-BAND and OverStitch. The Company's product, ORBERA, is a gastric balloon. The ORBERA Intragastric Balloon System is a weight loss aid for adults suffering from obesity. The LAP-BAND System is a minimally invasive procedure that offers weight loss. The LAP-BAND System is indicated for weight reduction for patients with obesity. The OverStitch Endoscopic Suturing System enables advanced endoscopic surgery by allowing physicians to place full-thickness sutures through a flexible endoscope. OverStitch offers solutions for defects in both the upper and lower gastrointestinal tract.

Industry

Medical Equipment & Supplies

Contact Info

1120 South Capital Of Tx Hwy

Building 1 Suite 300

+1.512.2795100

http://apolloendo.com

Executive Leadership

Todd Newton

Chief Executive Officer, Director

Stefanie L. Cavanaugh

Chief Financial Officer, Secretary

Bret Schwartzhoff

Vice President,North America Sales and Global Marketing

Christopher J. Gostout

Chief Medical Officer

Rick Anderson

Independent Director

Key Stats

2.00 mean rating - 2 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.1K

2018

0.1K

2019(E)

0.1K
EPS (USD)

2017

-2.010

2018

-1.920

2019(E)

-1.310
Price To Earnings (TTM)
--
Price To Sales (TTM)
1.12
Price To Book (MRQ)
6.06
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
530.74
LT Debt To Equity (MRQ)
530.74
Return on Investment (TTM)
-54.50
Return on Equity (TTM)
-41.98

Latest News

Latest News

BRIEF-Apollo Endosurgery Q4 Loss Per Share $0.42

* APOLLO ENDOSURGERY, INC. REPORTS FOURTH QUARTER AND FULL YEAR 2017 RESULTS

BRIEF-Apollo Endosurgery Announces MFDS Approval For Orbera Intragastric Balloon System

* APOLLO ENDOSURGERY ANNOUNCES MFDS APPROVAL FOR ORBERA INTRAGASTRIC BALLOON SYSTEM IN SOUTH KOREA, A NON-SURGICAL SOLUTION TO ASSIST PATIENTS WITH WEIGHT LOSS Source text for Eikon: Further company coverage:

BRIEF-Apollo Endosurgery Inc Files For Stock Shelf Of Upto $50 Million - SEC Filing

* APOLLO ENDOSURGERY INC FILES FOR STOCK SHELF OF UPTO $50 MILLION - SEC FILING Source text (http://bit.ly/2AONduG) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

BRIEF-Apollo Endosurgery Receives FDA Clearance For Overstitch Sx Endoscopic Suturing System

* APOLLO ENDOSURGERY RECEIVES FDA CLEARANCE FOR OVERSTITCH™ SX ENDOSCOPIC SUTURING SYSTEM

BRIEF-David Pacitti joins Apollo Endosurgery board of directors

* David C. Pacitti joins Apollo Endosurgery board of directors

BRIEF-Apollo Endosurgery reports qtrly loss per share $‍0.32​

* Apollo Endosurgery Inc - qtrly loss per share $0.32 Source text for Eikon: Further company coverage:

BRIEF-Apollo endosurgery announces CE mark approval for the Orbera365™ managed weight loss system,

* Apollo Endosurgery announces CE mark approval for the Orbera365™ managed weight loss system, expanding the indwell period from 6 months to 12 months with the gastric balloon category leader

BRIEF-Stonepine Capital Management Llc reports 13.7 percent passive stake in Apollo Endosurgery Inc

* Stonepine Capital Management Llc reports 13.7 percent passive stake in Apollo Endosurgery Inc as of August 11, 2017 - SEC filing Source text: (http://bit.ly/2xbQJty) Further company coverage:

BRIEF-Novo Holdings A/S reports 3.9 pct stake in Apollo Endosurgery as on Aug 14

* Novo Holdings A/S reports 3.9 percent stake in Apollo Endosurgery Inc as on August 14, 2017 - SEC filing

BRIEF-Apollo Endosurgery Q2 revenue $17.1 mln

* Apollo Endosurgery - total endo-bariatric revenues were $9.5 million for three months ended june 30, 2017, an increase of 13.0% compared to q2 of 2016

BRIEF-Apollo Endosurgery files amended S-1 registration statement

* Files amended S-1 registration statement, sees offering of 3.5 million shares of its common stock - SEC filing

BRIEF-Apollo Endosurgery files for stock shelf offering of up to $17.3 mln

* Apollo Endosurgery inc files for stock shelf offering of up to $17.3 million - sec filing Source text for Eikon: Further company coverage:

BRIEF-Apollo Endosurgery Q1 revenue falls 10 pct to $14.6 mln

* Qtrly loss per share $0.77 Source text - http://bit.ly/2pIXu3Q Further company coverage:

BRIEF-Apollo Endosurgery is a subject in federal false claims act investigation

* Apollo Endosurgery - in March 2017, co informed by department of justice that co is a subject in federal false claims act investigation

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up